INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10520660			
Filing Date		2005-01-10			
First Named Inventor	Hiromu HABASHITA				
Art Unit		1624			
Examiner Name	Zachary C. TUCKER				
Attorney Docket Number		Q85692			

U.S.PATENTS Remove								Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	)ate	of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1									
If you wish to add additional U.S. Patent citation information please click the Add button.										
U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>			of sited Desument		Releva	Columns,Lines where int Passages or Relev s Appear	
	1									
If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j		Kind Code4	Publication Date	Applicant of cited		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	т5
	1	03/059893	wo		A1	2003-07-24	ASTRAZENECA AB			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add										
NON-PATENT LITERATURE DOCUMENTS Remove										
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T5		

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

 Application Number
 10520660

 Filing Date
 2005-01-10

 First Named Inventor
 Hirorrus HABASHITA

 Art Unit
 1624

 Examiner Name
 Zachary C. TUCKER

 Attorney Docket Number
 Q85692

	1 RANSOHOFF ET AL., "Chemokine receptor antagonism as a new therapy for multiple sclerosis", EXPERT OPINION ON INVESTIGATIONAL DRUGS, Ashley Publications Vol. 9, no. 5, 2000, pages 1079-1097						
If you wis	h to ac	ld addit	tional non-patent literature document citat	ion information please click the Add b	utton Add		
			EXAMINER	SIGNATURE			
Examiner Signature		ture	/Jeffrey Murray/	Date Considered	02/15/2008		
			eference considered, whether or not citati				

¹ See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.